Nevertheless, even if the AUC value of methylated miR-129 and miR-935 were 0.83 and 0.79, respectively, in preclinical validation studies, the authors underlined the appropriate selection of the marker panel GHSR/MAL, which reached an AUC of 0.89 when distinguishing between BC patients and the controls. This evidence concerns the gene GHSR and breast cancer.